REG - Adv Medical Solutns. - Application for Admission

Advanced Medical SolutionsAnnouncement

10/09/2025 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20250910:nRSJ6759Ya&default-theme=true

RNS Number : 6759Y  Advanced Medical Solutions Grp PLC  10 September 2025

     10 September 2025

Advanced Medical Solutions Group plc

("AMS", the "Company" or the "Group")

 

Application for Admission

 

Winsford, UK: Advanced Medical Solutions Group plc (AIM: AMS), the
world-leading specialist in tissue-healing technologies, announces that an
application has been made to the London Stock Exchange for the block listing
of securities in respect of a total of 10,400,000 ordinary shares of 5 pence
each ("New Ordinary Shares") to be admitted to trading on AIM. Following the
admission of these Ordinary Shares, there will be no change to the Company's
current issued share capital, which consists of 219,330,534 Ordinary Shares
with voting rights.

 

The block listing application relates to New Ordinary Shares to be issued from
time to time pursuant to the exercise of share options under the Company's
existing schemes as follows:

 

 Scheme                                                        No. of New Ordinary Shares
 Employee Share Purchase Plan (ESPP)                           2,000,000
 Company Share Option Plan (CSOP)                              200,000
 Unapproved Executive Share Option Scheme (ESOS)               200,000
 Long-Term Incentive Plan (LTIP)                               4,000,000
 Group Share Option Plan (GSOP)                                4,000,000

 

In addition to the above, application has been made for 2,000,000 New Ordinary
Shares has been applied for under the Employee Share Purchase Plan, previously
named the Deferred Share Bonus Scheme.

 

An application has been made with respect to a new Block Listing for the Group
Share Option Plan of 4,000,000 New Ordinary Shares.

 

When issued, the New Ordinary Shares will be credited as fully paid and will
rank pari passu in all respects with the existing ordinary shares of 5 pence
each in the capital of Advanced Medical Solutions Group plc.

 

It is expected that admission will become effective for the Ordinary Shares
on 15 September 2025.

 

- End -

 

 

 

For further information, please visit www.admedsol.com
(http://www.admedsol.com) or contact:

 

 Advanced Medical Solutions Group plc             Tel: +44 (0) 1606 545508
 Chris Meredith, Chief Executive Officer

 Eddie Johnson, Chief Financial Officer

 Michael King, Investor Relations

 Optimum Strategic Communications                 Tel: +44 (0) 20 3709 5700
 Mary Clark / Nick Bastin / Isabelle Abdou        AMS@optimumcomms.com

 Investec Bank PLC (NOMAD & Broker)               Tel: +44 (0) 20 7597 5970
 Gary Clarence / David Anderson

 Berenberg (Joint Broker)                         Tel: +44 (0) 20 3207 7800
 Toby Flaux / Detlir Elezi / Yasmina Benchekroun

 

About Advanced Medical Solutions Group plc - see www.admedsol.com
(http://www.admedsol.com)

AMS is a world-leading independent developer and manufacturer of innovative
tissue-healing technology, focused on quality outcomes for patients and value
for payers. AMS has a wide range of surgical products including tissue
adhesives, sutures, haemostats, internal fixation devices and internal
sealants, which it markets under its brands LiquiBand®, RESORBA®,
LiquiBandFix8®, LIQUIFIX™, Peters Surgical, Ifabond, Vitalitec and
Seal-G®. AMS also supplies wound care dressings such as silver alginates,
alginates and foams through its ActivHeal® brand as well as under white
label. Since 2019, the Group has made seven acquisitions: Sealantis, an
Israeli developer of innovative internal sealants, Biomatlante, a French
developer and manufacturer of surgical biomaterials, Raleigh, a leading UK
coater and converter of woundcare and bio-diagnostics materials, AFS Medical,
an Austrian specialist surgical business, Connexicon, an Irish tissue
adhesives specialist, Syntacoll, a German specialist in collagen-based
absorbable surgical implants and Peters Surgical, a global provider of
specialty surgical sutures, mechanical haemostasis and internal cyanoacrylate
devices.

 

AMS's products, manufactured in the UK, Germany, France, the Netherlands,
Thailand, India, the Czech Republic and Israel, are sold globally via a
network of multinational or regional partners and distributors, as well as via
AMS's own direct sales forces in the UK, Germany, Austria, France, Poland,
Benelux, India, the Czech Republic and Russia. The Group has R&D
innovation hubs in the UK, Ireland, Germany, France and Israel. Established in
1991, the Group has more than 1,500 employees. For more information, please
see www.admedsol.com (http://www.admedsol.com) .

 

-

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  ALSBRGDCGXGDGUC